News

Disability worsening in people with neuromyelitis optica spectrum disorder (NMOSD) is largely driven by relapses, or episodes when new symptoms emerge or existing symptoms worsen, but it may also occur in the absence of such episodes. That’s according to a study analyzing international data from 261 NMOSD patients, which…

People with neuromyelitis optica spectrum disorder (NMOSD) who smoke have a higher risk of incomplete recovery after disease relapses than those who do not smoke, according to a review of published studies. Smoking did not appear to increase the risk of developing NMOSD or subsequent relapses, however. The relationship…

Acute attacks of neuromyelitis optica spectrum disorder (NMOSD) may be worsened by web-like structures released by immune cells that normally help fight infection, a study suggests. NMOSD patients experiencing disease attacks had higher blood levels of markers of these web-like structures, called neutrophil extracellular traps (NETs), relative to healthy…

A simple blood test measuring the levels of three proteins linked to brain damage and inflammation may help guide management of neuromyelitis optica spectrum disorder (NMOSD) related to antibodies against the AQP4 protein, a study suggests. People with NMOSD who were experiencing a disease relapse, when symptoms worsen,…

In a real-world study of adults living with neuromyelitis optica spectrum disorder (NMOSD) in Japan, Uplizna (inebilizumab) was linked to fewer relapses, generally stable disability, and less use of corticosteroids. In addition, the approved therapy’s safety profile was consistent with what had been observed in earlier studies. “Our…

Treatment with Soliris (eculizumab) substantially reduces the risk and frequency of relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against the aquaporin-4 (AQP4) protein. That’s according to a systematic review of published studies reporting results from clinical trials testing Soliris in this…

People with neuromyelitis optica spectrum disorder (NMOSD) report a greater burden of sleep problems and, when objectively monitored, spend more time in bed and sleeping than healthy people, according to a small study from Thailand. Data from 24 adults with NMOSD and self-reactive antibodies against the aquaporin-4 (AQP4) protein…

An international team of researchers identified a self-reactive antibody that may explain cases of neuromyelitis optica spectrum disorder (NMOSD)-like disease that test negative for known NMOSD-causing antibodies. Self-reactive antibodies against the protein modulator VRAC current 1 (MLC1) were identified in multiple people with NMOSD-like disease who lacked known disease-causing…

Treatment with Uplizna (inebilizumab-cdon) was associated with fewer attacks and reduced disability in Chinese adults with neuromyelitis optica spectrum disorder (NMOSD) who have anti-aquaporin-4 (AQP4) antibodies, a real-world study found. The estimated one-year attack-free rate was 95.5%. According to the researchers, the findings “provided evidence on the real-world…

MIL62, a treatment approved in China to treat neuromyelitis optica spectrum disorder (NMOSD), was superior to a placebo at preventing relapses and controlling disease activity in people with the autoimmune disease. That’s according to data from the Phase 3 portion of a China-based Phase 1b/3 clinical trial…